Group items tagged

Recognising the changing practices in healthcare, the Royal Pharmaceutical Society (RPS) has revised and updated its position on the separation of prescribing and dispensing or administration of a medicine by the same healthcare professional. It's previous guidance, published in March 2020, restricted prescribing and dispensing by the same healthcare professional only in exceptional circumstances. The new guidance, jointly developed with the Royal College of Nursing (RCN), has made prescribing and dispensing of medicines more flexible. It clarifies that "where there is a risk assessment in place and in the best interests of the patient, the same healthcare professional can be responsible for the prescribing and dispensing / supply / administration of medicines." The change in the position statement follows an extensive year-long engagement exercise with medical associations, members, fellows, expert advisory groups, patient groups and the RPS Country Boards.

In recent years, the healthcare sector has seen a significant transformation driven by the rapid advancement of technology. From improved patient care to streamlined administrative processes, technology has become an indispensable part of modern healthcare. As medical facilities worldwide embrace these innovations, it's essential to understand why the sector leans so heavily on advanced technological solutions. Below are seven key reasons illustrating the crucial role of technology in healthcare. Enhanced Radiology Workflows Advancements in technology have revolutionized radiology workflows, making the process more efficient and accurate. Digital imaging technologies, such as PACS (Picture Archiving and Communication Systems) and RIS (Radiology Information Systems), allow for the seamless storage, retrieval, and sharing of medical images. The specialists AbbaDox say that this reduces the time needed to diagnose and treat patients, significantly improving the overall efficiency of radiology departments. Additionally, AI-powered tools can assist radiologists by highlighting potential areas of concern within images, ensuring that abnormalities are not overlooked. These improvements contribute to faster, more accurate diagnoses and better patient outcomes.

At the Future of Britain Conference 2024, the newly appointed Secretary of Health and Social Care, (DHSC) Wes Streeting, stated that "Labour's DNA is in the NHS". He also called for a long-term approach to reform the broken health sector and the integration of artificial intelligence (AI) to steer the healthcare system towards sustainability and growth. Hosted by Tony Blair Institute for Global Change and My Life My Say today, Tuesday, 9, Streeting discussed the plans to fix the healthcare system and role of Artificial Intelligence (AI) in "making the right choices" by bringing in three essential shifts in the healthcare. Criticising the previous Conservative administration for leaving "massive burning deck issues" due to constant reshuffling within the Department of Health and Social Care (DHSC), Streeting lamented that this "instability" and "indecisions" have made comprehensive reform even more pressing. Drawing inspiration from Chancellor Rachel Reeves' speech on economic growth, Streeting stressed the interconnectedness of health and economic prosperity.

The healthcare landscape has dramatically changed over the years, due to a number of factors, firstly having to navigate Covid-19 and now the advancement of artificial intelligence (AI) and machine technology, to name a few. As a result, training the next generation of healthcare leaders is more important now than ever. Let's look at three ways to effectively train the next generation of pharmacists: Robust Induction Programme Induction programs are an effective way of training the next generation of pharmacists as they have the ability to provide knowledge, skills and practical experience to deal with and manage common challenges they're likely to experience in their careers. These programs usually include training in pharmacokinetics, drug dosages, medication administration, and pharmacotherapy.

"We're thrilled that MedicinesComplete will now be available to all clinicians in Wales through the NHS Wales e-Library," said Karen Baxter, Managing Director of Pharmaceutical Press, announcing a contract with NHS Wales. The collaboration between Pharmaceutical Press, the Royal Pharmaceutical Society's knowledge business, and NHS Wales is set to grant healthcare professionals across Wales unlimited access to MedicinesComplete. MedicineComeplete is a vital resource for accurate and trusted medicines information, includes key resources such as the British National Formulary, Stockley's Drug Interactions, and Martindale: The Complete Drug Reference and will be accessible through the NHS Wales e-Library, managed by Digital Health and Care Wales. The collaboration effective starting September 1, 2024, aims to significantly enhance patient safety and improve healthcare outcomes by providing time-pressured clinicians with instant access to essential, evidence-based guidance. According to Baxter the new collaboration "will better enable health professionals across primary and secondary care to make confident decisions about medicines, ensuring patients get the best from their treatment." Moreover, MedicinesComplete has made it easy for health professionals globally to access trusted medicines information since 2004, provided expert guidance on the safe use and administration of drugs and medicines, in one place.

Rowlands Pharmacy has joined hands with healthcare software company HasHealth for an enhanced digital proposition to facilitate seamless delivery of a raft of clinical services including flu and travel vaccinations. The new system is now available across 400 Rowlands pharmacies across the UK. The partnership comes as Rowlands Pharmacy strives to provide patients with a seamless booking experience whilst minimising time-consuming administration for pharmacy staff, with its waiting list, medical pre-screen questionnaires and resource management capabilities, the company said in a statement. HasHealth offers a virtual healthcare software solution that allows community pharmacies to schedule, manage, and communicate with patients easily online. It combines its cutting-edge video technology with booking and management software, which can be adapted to any clinical service. Nigel Swift, managing director at Rowlands Pharmacy, commented: "We pride ourselves on listening to our staff, based on feedback we knew we could do better with our digital proposition for clinical services and flu vaccinations in particular.

Over-the-counter (OTC) medicines can empower customers and pave the way for a sustainable healthcare future. By embracing OTC products, pharmacies can achieve greater freedom, stability, and enhanced profitability. In our exclusive interview with Anna Maxwell, founder and CEO of pioneering consumer healthcare company Maxwellia, we explore their game-changing pharmacy brands leading the way in self-care. Why pharmacies should embrace OTC medicines? There's never been a more critical time for pharmacies to lean into the OTC space. Right now, about 90 per cent of pharmacy income in the UK is tied to NHS funding-a model that's increasingly unsustainable.[1] We all value the NHS, but it simply can't afford to cover every treatment at the point of use indefinitely. If pharmacies could achieve even a modest shift in NHS reliance this would mean more freedom, stability, and profitability for the business. OTC medicines are the key to making that happen, offering a way to quickly provide, effective treatments that help customers while reducing the administrative and financial burdens on pharmacists.

Pharmacy First has demonstrated the enormous value of community pharmacy in providing accessible front-line care. However, pharmacists continue to face several challenges in delivering the service. "Pharmacy First is a success, but it needs proper support to reach its full potential," said Numark chairman Harry McQuillan. In the first year alone, community pharmacies in England delivered an incredible 2 million consultations, highlighting the vital role pharmacists and their teams play in supporting the NHS. "This significant number shows the high demand for accessible healthcare and the trust patients place in their local pharmacy teams. It's clear that when empowered, community pharmacy delivers," McQuillan told Pharmacy Business. Key challenges in providing the service While Numark members have embraced Pharmacy First, McQuillan pointed out several challenges that persist: "Workforce capacity continues to be a concern, with patient demand sometimes outpacing available resources. "The administrative burden, particularly around IT interoperability, data capture, and reimbursement processes, adds complexity." "Additionally, some geographical areas are still struggling with public awareness, meaning more work is needed to ensure patients understand when and how they can access Pharmacy First."

The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the marketing authorisation of Adtralza, a dermatological solution developed by Danish specialist LEO Pharma. This injectable solution contains 300 mg of tralokinumab in a 2 mL pre-filled pen and will be available for tralokinumab patients in the UK from early 2024. Tralokinumab is indicated for treating moderate-to-severe atopic dermatitis in adult and adolescent patients aged 12 and older who require systemic therapy, Leo Pharma said in a statement. It is a fully human monoclonal antibody developed to specifically bind to and inhibit the IL-13 cytokine. Previously, it was available in a 150 mg in 1 mL pre-filled syringe. According to Leo Pharma, the 300 mg tralokinumab in a 2 mL pre-filled pen offers a streamlined administration for both patients and prescribers. It begins with an initial 600 mg dose in two injections, followed by a single 300 mg maintenance dose administered every other week. "We're pleased that this simplified administration method for tralokinumab will soon benefit eligible atopic dermatitis patients in the UK. It aligns with our commitment to elevate the standard of care and support for individuals with skin conditions," said Leanne Walsh, Vice President and General Manager of UK and Ireland at LEO Pharma.

The healthcare rules in the 21st century keep changing and more frequently in the post-pandemic era. Ordinarily, physicians have limited time for administrative tasks; however, recent developments have made their time even more crucial. One comprehensive answer to resolve financial troubles once and for all is to hire a medical billing service. A medical billing company files, follow-ups, and collects from insurance companies on behalf of providers.

"The COVID-19 pandemic is confronting medical practices with unique operational challenges. Some practices have turned to telemedicine. Some providers are finding it difficult to continue operating at all, with sweeping cancellations of elective procedures and discouragement of in-person office appointments. Economic fallout due to the virus's effects on virtually every person, everywhere, is another concern facing all aspects of all healthcare systems..."

The Drug Enforcement Administration is changing regulation for prescribing controlled substances via telemedicine. Here's what medical professionals need to know about the adjustments to these policies. Read more: https://www.hospitalrecruiting.com/blog/8673/the-dea-telemed-prescription-rules-are-here-to-stay/?utm_source=social_media&utm_medium=blog&utm_campaign=social_posting #dea #telemedicine #healthcare #medicalnews #physician #doctor #healthcarenews

When you visit a hospital, one of the last things that come to mind is worrying about legal aspects and what rights you might have - or lack. But these issues and your understanding of them are more important than ever. Knowing exactly what hospitals can legally and cannot do to you is an essential part of ensuring your protection as a patient when going in for care. In this blog post, we'll break down the legal details behind being treated at a hospital so that you can feel more confident when making healthcare decisions. Let's dive into the legal aspect of visiting a hospital, outline what hospitals can and cannot do to us, discover our rights as patients, and review any other considerations worth keeping in mind! OVERVIEW OF MEDICAL MALPRACTICE LAW AND HOW IT RELATES TO VISITING A HOSPITAL When going to a hospital, concerned patients and their families should be aware of the legal risks posed in medical malpractice cases. These potential issues can have life-altering consequences if misdiagnoses, wrong medication administration, or improper treatment occurs. Now, whether you seek damages for your injuries at Staten Island University Hospital or in a different hospital in your hometown, it is important for visitors to understand that the law has set forth regulations regarding acceptable standards of care expected by our nation's hospitals. Those regulations can include procedures of qualified professionals that protect patients from financial exploitation and physical or emotional distress caused by medical negligence. Understanding how this information applies to you will help you protect yourself legally if your rights are violated while visiting a hospital.

The American healthcare company, CVS Health, has decided to remove the cold and cough pills containing phenylephrine from the drug stores. The following decision comes after the health regulator, the US Food and Drug Administration (FDA) determines the decongestant is ineffective towards flu if taken orally. However, when ingested in pill or tablet form, this ingredient fails to reach its destination from the stomach to the nasal passages. CVS Health spokesperson told USA Today, "We are removing a small number of oral decongestant products that contain phenylephrine as the only active ingredient from CVS Pharmacy stores but will continue offering many other oral cough and cold products to meet consumer needs." They almost run more than 9,000 stores in the US whereas their rival, Walgreens has not yet taken the step to remove over-the-counter medications from their shelves.

The administrative burden on physicians and medical billing services has been a constant worry. CMS administrator and American health policy consultant Seema Verma considerably acknowledges this concern and has asked insurance companies to modify their policies to rectify problematic areas.

The Independent Pharmacies Association (IPA), in collaboration with the Association of Optometrists (AOP), the British Dental Association (BDA) and the NHS Confederation has written to health secretary Wes Streeting, urging him to ensure sustainable investment in primary care to strengthen the NHS and better serve patients. In their letter, the group congratulated Streeting on his recent appointment as Secretary of State for Health and Social Care and requested a meeting to provide their joint constructive input towards improving health outcomes. They expressed concern that recent administrations have failed to follow through on promises to properly integrate and fund primary care, leading to deteriorating health outcomes. "Our collective experience is that our National Health Service (NHS), and health outcomes generally, have suffered at the hands of recent administrations that have talked much about the importance of properly integrating and funding primary care but not followed through with action," they wrote. The associations emphasised the need to transition the NHS to a Neighbourhood Health Service, where more care is delivered within local communities to identify problems earlier.

The Pharmacists' Defence Association (PDA) has issued an advisory information to community pharmacy contractors about Paxlovid antiviral treatment for non-hospitalised patients. "Patients will be assessed to see if they meet the criteria for inclusion and will need careful checking to see if Paxlovid therapy is safe due to the significant number of drug interactions. Assessment and prescribing are provided via dedicated services with dispensing and supply arranged by the central supply service or via participating community pharmacies," said the PDA. Every pharmacist can support this service by making themselves familiar with the service set up in their area. This is so that they can provide advice and signpost to healthcare colleagues and patients. Pharmacists working in general practice may also be able to help with identifying newly diagnosed highest risk patients. Whilst most of this group should have already been identified and contacted, no system is entirely foolproof. The PDA's advisory note provides information around indemnity and links to information about the prescribing and administration of Paxlovid since it is being provided under a temporary authorisation, and is subject to numerous drug-drug interactions, and is a recommended first-line treatment.

Millions of people take dietary supplements every day, hoping to improve their health in some way. But how much do you know about these supplements? Are they safe? Do they work? And are there any risks associated with taking them? Here are six important things to know about dietary supplements if you're one of the people who take them. NOT ALL SUPPLEMENTS ARE REGULATED Since dietary supplements are not drugs, they do not need to be approved by the Food and Drug Administration (FDA) before they can be sold. This means that some products may not contain what is stated on their labels or may even include ingredients that could be dangerous. Therefore, it's important to always read labels and do your research before committing to one. Furthermore, make sure you purchase your supplements from a reputable source. This means that you should look for companies that have been independently tested and certified to provide high-quality products. MAKE SURE THE SUPPLEMENT IS RIGHT FOR YOU Before taking any dietary supplement, check with your doctor or healthcare professional first. This is especially important if you have a medical condition or are on medication, as certain supplements may interact in unwanted ways. Just because something is labeled as "natural" doesn't necessarily mean it's good for you or that you even need to take it. Before taking any supplement, talk to your doctor about whether or not it could be beneficial for you and how much you should take.

British health agencies have secured funding to develop a standardised approach to test the performance of vaccines being used or in development against monkeypox, days after the World Health Organization labelled the growing outbreak a global health emergency. The Coalition for Epidemic Preparedness Innovations (CEPI) said it would give up to $375,000 to the Medicines and Healthcare products Regulatory Agency (MHRA) and Health Security Agency (UKHSA) to develop standard tools to assess the strength and duration of immune responses generated by current vaccines, and for tests used to detect monkeypox antibody levels. Apart from administration fees, these tools will be made freely available to the global scientific community, paving the way for a common standardised assessment between countries documenting vaccine performance against monkeypox, CEPI said. Until this year, the viral disease has rarely spread outside Africa where it is endemic. But reports of a handful of cases in Britain in early May signalled that the outbreak had moved into Europe. So far, there have been more than 16,000 confirmed cases of monkeypox in more than 75 countries.

Pharmaceutical recalls are complicated and expensive, just like in any other business. Pharmaceutical recalls, however, pose a further risk because they might change both short- and long-term health effects. To ensure smooth recalls with few negative effects on public health, it is crucial to understand the pharmaceutical product recall procedure and the roles of each key player. Throughout the recall procedure, patient safety is crucially ensured by the FDA, pharmaceutical companies, pharmacy technicians, and other healthcare professionals. Learning about pharma recalls, procedures, and responsibilities is essential for guaranteeing patient safety for key actors like the Food and Drug Administration (FDA), manufacturers, and other medical specialists. RECALL CLASSIFICATIONS Recalls can fall into one of three categories-class I, II, or III-with class I being the most serious and lethal. Products that have the potential to result in serious, permanent complications or death are subject to Class I recalls. Class II recalls are recommended for product flaws that have a low likelihood of harmful events or that can result in reversible side effects. Last but not least, class III recalls typically arise from problems with packaging that do not pose a risk. Since they are frequently issued out of an abundance of prudence rather than due to any negative impacts, many people may even describe this kind of recall as benign.